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HIF prolyl hydroxylase inhibition protects
skeletal muscle from eccentric contractioninduced injury
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Deepak K. Rajpal3, Guizhen Luo1, Henning Fritz Kramer1, Robert S. Geske3, Frank Fang4, Bert Yao2, Richard V. Clark1,
John Lepore2, Alex Cobitz2, Ram Miller1, Kazunori Nosaka5, Aaron C. Hinken1 and Alan J. Russell1*

Abstract
Background: In muscular dystrophy and old age, skeletal muscle repair is compromised leading to fibrosis and
fatty tissue accumulation. Therefore, therapies that protect skeletal muscle or enhance repair would be valuable
medical treatments. Hypoxia-inducible factors (HIFs) regulate gene transcription under conditions of low oxygen,
and HIF target genes EPO and VEGF have been associated with muscle protection and repair. We tested the
importance of HIF activation following skeletal muscle injury, in both a murine model and human volunteers, using
prolyl hydroxylase inhibitors that stabilize and activate HIF.
Methods: Using a mouse eccentric limb injury model, we characterized the protective effects of prolyl hydroxylase
inhibitor, GSK1120360A. We then extended these studies to examine the impact of EPO modulation and infiltrating
immune cell populations on muscle protection. Finally, we extended this study with an experimental medicine
approach using eccentric arm exercise in untrained volunteers to measure the muscle-protective effects of a clinical
prolyl hydroxylase inhibitor, daprodustat.
Results: GSK1120360A dramatically prevented functional deficits and histological damage, while accelerating
recovery after eccentric limb injury in mice. Surprisingly, this effect was independent of EPO, but required myeloid
HIF1α-mediated iNOS activity. Treatment of healthy human volunteers with high-dose daprodustat reduced
accumulation of circulating damage markers following eccentric arm exercise, although we did not observe any
diminution of functional deficits with compound treatment.
Conclusion: The results of these experiments highlight a novel skeletal muscle protective effect of prolyl
hydroxylase inhibition via HIF-mediated expression of iNOS in macrophages. Partial recapitulation of these findings
in healthy volunteers suggests elements of consistent pharmacology compared to responses in mice although
there are clear differences between these two systems.
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Introduction
Under conditions of trauma or extreme physical exercise,
skeletal muscle damage occurs and sets off an orchestrated series of events to replace and repair damaged tissue [1]. The dynamics of this process can be disrupted by
chronic inflammation and age, resulting in inefficient replacement of muscle and the accumulation of connective
tissue and fat [2, 3].
The transcription factor hypoxia-induced factor 1α
(HIF1α) is a primary regulator of the homeostatic response
to hypoxia [2], and several lines of evidence point to the importance of hypoxic response to skeletal muscle repair.
Both HIF1α and the HIF-target gene, VEGF, are elevated by
strenuous exercise [4, 5], and VEGF stimulates muscle
angiogenesis and myoblast proliferation [6]. Another
HIF-target gene, erythropoietin (EPO), also stimulates myoblast proliferation and muscle recovery after injury. One of
the primary mediators of HIF1α activity in muscle is local
oxygen concentration, which can drop significantly during
exercise or injury [7, 8]. Under normoxic conditions,
oxygen-regulated HIF proteins (primarily HIF1α, HIF2α)
are hydroxylated and targeted for proteasomal degradation
by HIF-prolyl 4-hydroxylases (PHD1,2,3) which require
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molecular O2 for activity. Under low oxygen tension, PHD
activity is reduced, stabilizing HIF and allowing transcription of target genes [9]. Recently, small molecule inhibitors
of PHD proteins have been identified that stabilize HIF in
vivo [10]. We took advantage of these pharmacologic tools
to test the hypothesis that acute HIF activation would protect against muscle damage induced by lengthening (eccentric) muscle contractions and accelerate muscle repair in
both mice and humans.

Results
Skeletal muscle is subject to dramatic changes in length and
strain during contraction. One of the transcription factors involved in initiating the tissue response to acute exercise was
recently shown to be HIF1α [11]. We asked whether inhibiting PHD enzymes would be beneficial for muscle repair after
injury. Using eccentric, lengthening contractions to cause
acute muscle damage with subsequent inflammation and tissue remodeling [12] via a non-invasive footplate system in
the gastrocnemius muscle of mice [13], muscle force was decreased on average by 30–40%, but fully recovered to the initial force after 30 days. In contrast, daily dosage of the PHD
inhibitor GSK1120360A (GSK360) [14], starting 10 min after
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Fig. 1 Prolyl hydroxylase inhibitors protect skeletal muscle from exercise-induced injury. a Maximal limb force in mice before and after eccentric
muscle exercise. Mice were treated with vehicle or GSK360 daily, starting 10 min after eccentric exercise. Limb force was measured for 28 days.
Uninjured limb force included as a control. Data are normalized to pre-exercise force (n = 8). b Representative images of immunohistochemical
staining for albumin (red), laminin (green), and nuclei (blue) in gastrocnemius muscle 3 days after eccentric exercise (n = 4/group). Upper panels:
low power images of full cross section of gastrocnemius. Lower panels: higher magnifications of the rectangular areas above (scale bars =
250 μM). Arrows: albumin-positive myofibers. Asterisks: albumin-negative fibers. c Quantification of albumin-positive fibers measured as a
proportion of total fibers (n = 4/group). d Maximal limb force in mice before and after eccentric muscle damage. Mice were treated daily with
vehicle or GSK360 24 h before, at the time of injury, or 24 h after eccentric exercise. Limb force was measures for 8 days (n = 8). Data shown as
the mean ± SEM. Two-way ANOVA followed by Holm-Sidak’s test corrected for multiple comparisons; *P < 0.05, **P < 0.01, ***P < 0.001 versus
vehicle-dosed cohort (unless otherwise indicated)

Billin et al. Skeletal Muscle

(2018) 8:35

injury, provided a significant protective effect at 24 h and full
restoration of muscle force 9 days after damage (Fig. 1a,
Additional file 1: Figure S1a). Furthermore, we found that
fluorescent albumin incorporation was decreased by 70%
3 days post-injury with GSK360 treatment (Fig. 1b, c), indicating PHD inhibition also resulted in histological evidence
of muscle protection.
As we saw a biphasic GSK360 effect on force recovery,
we asked whether removing the initial protection from
injury would still result in accelerated recovery. Instead
of dosing at the time of injury, we delayed the initial
dose of GSK360 until 24 h post-eccentric damage. Under
these conditions, we found that recovery was still accelerated compared to control animals (Fig. 1d; GSK360
24 h post-injury), indicating that activation of hypoxic
signaling both decreased initial injury and accelerated
muscle recovery.
Dosing with GSK360 has been shown to induce EPO
production in vivo [14]. As EPO has been previously linked
to improved muscle repair after injury [15], we tested
whether the elevation of EPO by GSK360 was responsible
for its protective effects. At the maximal effective dose
(10 mg/kg) of GSK360, we found elevations in circulating
EPO, but not VEGF (Fig. 2a, b). We then treated mice daily
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with recombinant EPO, with or without an EPO neutralizing antibody, beginning 2 days prior to eccentric
injury to elucidate the effects of GSK360-induced
EPO production on muscle recovery. Recombinant
EPO was protective to muscle if administered before
injury (Fig. 2c). However, pre-dosing with either an
EPO neutralizing antibody, or a soluble EPO receptor
decoy [16] prior to GSK360 treatment did not alter
GSK360’s protective muscle effects (Fig. 2d, e), while lowering Hct and RBC counts (Additional file 1: Figure S1b, c),
suggesting that the protection afforded by GSK360 was not
dependent on EPO.
That EPO was not required for muscle protection with
GSK360 indicated another mechanism through which
PHD inhibition might affect muscle injury, possibly via
HIF1α upregulation in muscle itself. HIF1α protein was
transiently elevated in compound treated muscle after
injury (Fig. 2f ), so we surveyed the early transcriptional
effects of GSK360 in damaged muscle. Unexpectedly,
we found no significant transcriptional changes specific to treatment in muscle (Additional file 2: Figure
S2a, Additional file 3: Table S1) and that compound
concentration in muscle was low relative to other organs
(Additional file 2: Figure S2b), together suggesting another
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Fig. 2 Prolyl hydroxylase inhibitors exert their protective effects independently of EPO. a Serum EPO concentration and b Serum VEGF
concentration after oral administration of 10 mg/kg GSK360 in mice (n = 8). c Force deficit 24 h after eccentric injury. Mice were treated
daily with rEPO, with and without an EPO neutralizing antibody (n = 8). d Force deficit 24 h after eccentric injury of mice co-treated with
EPO neutralizing antibody and GSK360 (n = 8). e Force deficit 24 h after eccentric injury of mice co-treated with soluble EPO receptor and
GSK360 (n = 8). f Western blot of HIF1α protein levels from muscle lysates 1 h and 24 h after limb injury. GAPDH used as a loading control
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tissue compartment was potentially responsible for the effects on muscle repair.
One possible effector that may play a role in the blunting of damage and acceleration of recovery would be the
immune response following muscle damage. Cells of the
myeloid lineage dominate muscle infiltrates after damage
[17], and myeloid Hif1a knockout (HIF1α KO) mice exhibit delayed recovery after muscle trauma [8] although
this finding has been recently disputed [18]. Using myeloid HIF1α KO mice, we asked whether altering hypoxic
signaling in immune cells would affect recovery from
muscle injury. Using the same eccentric damage protocol as before, we found that GSK360 was not protective
in either myeloid HIF1α KO homo- or heterozygous
mice (Fig. 3a), implicating HIF activation in myeloid cells
in the muscle-protective response to GSK360.
Early myeloid infiltration into injured muscle is dominated by neutrophils and macrophages, with macrophages
increasing in number and activity by 24 h after acute injury [19] (Additional file 2: Figure S2c). As macrophages
play an important role in promoting skeletal muscle protection and repair [20], we asked whether HIF-responsive
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macrophages, rather than neutrophils, drove the primary
GSK360 response in the muscle. To do so, we cultured
bone marrow-derived macrophages (BMDMs) from both
myeloid HIF1α KO and myeloid HIF1α expressing mice.
The plasma membranes of these BMDM were fluorescently labeled with PKH67-green and injected intramuscularly into the gastrocnemius of myeloid HIF1α KO mice
immediately following eccentric injury. Adoptive transfer
of HIF1α expressing macrophages re-established the protective effect of GSK360 seen in wild-type mice (c.f. Fig. 1),
in contrast to those muscles that received HIF1α-deficient
BMDM (Fig. 3b). FACS analysis of the myeloid cell population recovered from the gastrocnemius muscles 24 h following injury confirmed that most of the PKH67-green
cells were positive for the macrophage marker, CD11b+
(Fig. 3c). We conclude that GSK360’s protective effects
are mediated through HIF activation and signaling in
macrophages.
Macrophages are highly responsive to hypoxic signaling, with HIF1α regulating a number of genes that may
contribute to muscle protection including TNFα, IL-1β,
iNOS, and VEGF [21]. Our primary focus was on iNOS

Fig. 3 Prolyl hydroxylase inhibitors exert their protective effects via macrophage HIF1α and iNOS. a Force deficit 24 h after eccentric injury in
indicated strains of myeloid HIF1α KO mice administered vehicle or GSK360 (n = 8). b Force deficit 24 h after eccentric injury in myeloid HIF1α KO
mice with exogenous BMDM (either HIF1α KO or WT) injected intramuscularly following eccentric injury and treated with vehicle or GSK360
(n = 8). c FACS analysis of PKH67-green labeled myeloid populations recovered from injured muscles 24 h after injection and treatment. d Force
deficit 24 h after eccentric injury in WT mice treated with vehicle, iNOS inhibitor 1400 W and/or GSK360. Right side; force deficit 24 h after
eccentric injury in iNOS KO mice administered vehicle or GSK360 (n = 8). e iNOS gene expression measured by qPCR. Bone marrow-derived
macrophages (BMDM) were cultured and polarized to promote classical M1 or M2 activation or left inactivated (M0) and treated with vehicle or
GSK360 for 24 h. f iNOS protein expression in M1-polarized macrophages treated with GSK360 for 24 h before protein analysis by Western blot.
Rab5 was used as a loading control. All data in the figure are shown as the mean ± SEM. Two-way ANOVA followed by Holm-Sidak’s test
corrected for multiple comparisons; *P < 0.05, **P < 0.01, ***P < 0.001 versus the vehicle dosed cohort (unless otherwise indicated)
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as both nitric oxide [22] and iNOS itself [23] are regulators of myogenesis and muscle repair. Furthermore, they
are highly expressed by classically activated M1 macrophages found to be present within the first 24 h following muscle injury [24], fitting the timeframe in which
GSK360 appeared to be working. We first manipulated
NO activity with pharmacological tools, co-treating mice
with both GSK360 and 1400 W, an iNOS inhibitor [25].
The addition of 1400 W blunted the GSK360 effect on
muscle injury (Fig. 3d). We also measured force production after eccentric contractions in an iNOS KO mouse
[26]; similarly to inhibiting iNOS, GSK360 failed to protect muscle after eccentric injury (Fig. 3d). Treating
BMDM in culture with GSK360 resulted in increased expression of HIF1α only in classically activated M1 macrophages (Additional file 2: Figure S2d), along with a
dramatic increase in iNOS expression (Fig. 3e, f ).
Together, these data point to PHI mediating a protective
effect in muscle via activation of HIF1α in macrophages
and the subsequent upregulation of iNOS.
In humans, performing unaccustomed eccentric exercise
also leads to tissue damage, functional deficits, and muscle
pain often referred to as delayed onset muscle soreness
[27]. We took advantage of this to test the ability of a clinical stage PHI, daprodustat [28], to reduce muscle damage
in healthy volunteers subjected to eccentric exercise of the
elbow flexors in a double-blind placebo-controlled study.
Daprodustat is structurally related to GSK360 and in preclinical studies also protected mice from functional deficits
after eccentric injury (Additional file 4: Figure S3a). Subjects performed 30–60 contractions of their non-dominant
arm to induce more than 40% strength loss immediately
post-exercise and then were randomized to receive a total
of five doses of either placebo or daprodustat (Fig. 4a). Arm
function was measured as maximum voluntary contraction
(MVC) force generated at a fixed elbow joint angle of 90o
and was recorded 10 min pre-exercise and 5 min, 30 min,
24 h, 48 h, and 72 h post-exercise. We also measured range
of motion and serum muscle proteins over 3 days. The
study was arranged in two separate cohorts of placebo vs
5 mg daprodustat, and placebo vs 50 mg daprodustat
(Additional file 5: Table S2 describes demographic data).
There were 15 total adverse effects; none serious or
thought to be compound-related, with the most frequent
being exercise-induced arm muscle pain (myalgia,
Additional file 6: Table S3). Both MVC force and range of
motion were reduced by exercise but were not altered
with either dose of daprodustat (Fig. 4b, Additional file 4:
Figure S3b). However, increases in serum creatine kinase
activity after exercise were significantly lower in individuals administered 50 mg daprodustat (Fig. 4c).
We pursued an aptamer-based proteomics approach
to identify additional circulating markers of muscle injury and the effects of daprodustat treatment in serum
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from the placebo and 50 mg daprodustat groups (Somalogic, Inc.). Comparison of pre- and post-injury serum in
the placebo group revealed that 9 of 11 proteins increased
with exercise were associated with skeletal muscle and
were all lowered by daprodustat (Fig. 4d, Additional file 7:
Table S4). These changes are consistent with the mouse
data, suggesting a reduction in tissue damage after muscle
injury with HIF prolyl hydroxylase inhibition.

Discussion
PHD regulation of HIF1α has been implicated in the
protection of the heart, brain, and liver after an ischemic
insult [14, 29, 30]. The mechanism of this protection appears to vary by tissue type and often reflects the effect
of chronic HIF1α activation, robust target gene activation, and tissue remodeling after PHD protein knockout.
Compared to these reports, we were surprised by both
the acute nature of the skeletal muscle protective effect
and its modest transcriptional response in muscle in our
preclinical system. Higher doses (30 mg/kg) of GSK360
have been associated with HIF1α target gene activation
in muscle [14], but our studies identified a more sensitive myeloid population that drives muscle protection in
an iNOS-dependent manner without large scale transcriptional responses. iNOS is required for the efficient
recovery of skeletal muscle after injury in mice [23], but
to our knowledge, this is the first time that iNOS has
been implicated in an acute protective role after muscle
injury. In skeletal muscle ischemia-reperfusion injury,
iNOS is generally associated with a delayed inflammatory response and leads to high NO levels, membrane
lysis, and skeletal muscle breakdown [31]. A complex
balance exists between protective and detrimental effects
of NO dependent upon the time and extent of NO release [32]. Therefore, we presume that the modest inflammatory response and NO generation associated with
eccentric contraction-induced muscle injury leads to a
greater protective role for NO generated through iNOS.
We demonstrate that the macrophage HIF1α compartment is essential for the protective effect of PHD inhibition, which is consistent with their presumed role in
membrane repair after eccentric contraction-induced
muscle injury [20]. The exact mechanism by which the
hypoxic response generated by PHD inhibition in macrophages is driving the protection and recovery from the
muscle injury is as yet undetermined, but it is likely to
either be remodeling the inflammatory response or accelerating satellite cell activation [33]. GSK360 and
daprodustat are both non-selective inhibitors of PHD1,
2, and 3 [14, 34], and polarized macrophages express all
three PHD isoforms [35], making determination of
which isoform(s) are required for muscle protection difficult without more detailed studies. In preliminary experiments, GSK360 treatment of M1/M2 polarized
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Fig. 4 Prolyl hydroxylase inhibitor daprodustat reduces markers of muscle damage in healthy male volunteers after eccentric exercise. a Clinical
study design. b Maximum voluntary force at an arm angle of 90o before and after eccentric exercise in two separate studies. Boxed area represents a
75% range of values; central line indicates the median and the cross the mean value. Individual values are displayed to the left (top figure, placebo
n = 14, daprodustat 5 mg n = 12; bottom figure, placebo n = 15, daprodustat 50 mg n = 15). c Serum creatine kinase before and after eccentric exercise
in the two separate studies. d Heatmap and hierarchical clustering of the top 16 serum proteins changed between pre-exercise and 3 days post
exercise and the effect of 50 mg daprodustat on their levels. The first two columns display fold changes pre- vs. postexercise for daprodustat-treated
and placebo-treated participants, respectively. The third column shows daprodustat fold change treated vs. placebo-treated samples postexercise.
Protein names in bold denote a significant association with muscle-related phenotypes and/or pathways (each group n = 15). All data in the figure are
shown as the mean ± SEM. Repeat measure ANOVA for multiple comparisons; ***P < 0.001)

BMDM cells resulted in the upregulation of both inducible PHDs (PHD2 and PHD3) in M1 but not M2 macrophages (data not shown). This would suggest reflex
compensation from elevated HIF1α in M1 cells but does
not suggest which key PHD(s) are driving this response.
While healthy volunteer data did not recapitulate the
functional protection of PHI seen in mice, circulating
markers of muscle damage were reduced by daprodustat
in the highest dose group. This is possibly due to differences between these two systems. The cause of voluntary
strength deficits in people after eccentric exercise are not
well understood [36] and are associated with modest
changes in histological and inflammatory markers of
muscle damage [37, 38] compared to the more robust
damage we observed in mouse models. Force deficits in
people can also occur without elevation of circulating
markers of muscle damage after preconditioning exercise

[39], suggesting that mechanisms independent of histological damage, such as excitation-contraction coupling
failure [36], may be the determinants of human functional
deficits. Further, voluntary muscle contraction in humans
removes the contribution of factors such as muscle pain
to reductions in arm strength, which are not captured by
involuntary electrical stimulation in the mouse. We also
note that the volunteers used in this study were somewhat
overweight (mean BMI 26–28.5), possibly due to the entry
requirement for no regular exercise, a factor that could
also influence the outcome of the study.
Notably, the circulating signature of muscle-related
proteins elevated by exercise and decreased by daprodustat treatment in human volunteers is remarkably similar
to that observed in muscular dystrophy patients [40].
This likely reflects similarities between muscle injury
after eccentric exercise in healthy individuals and muscle
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injury due to structural fragility in dystrophic patients.
Further research is underway to understand if muscle
protection through PHD inhibition may provide protection in the background of muscular dystrophy.

days − 3 and 1 prior to eccentric damage. For EPO depletion studies, 200 μg/kg of a soluble EPO receptor (R&D
Systems, 1390-ER-050) was injected SC twice a day for
3 days prior to eccentric damage.

Conclusion
We have uncovered a novel connection between HIF1α
and iNOS that contributes to muscle protection after
exercise-driven injury in mice. Evidence suggests that
some elements of this protective effect may also be competent in healthy volunteers after eccentric injury, although there are clear differences in the magnitude of
response between mouse and man. Our data implicates
the HIF signaling axis as an important modulator of inflammatory activity during skeletal muscle repair and injury and further indicates that this mechanism may be of
therapeutic importance in the treatment of acute muscle
injury.

In vivo muscle contractility

Materials and methods
Preclinical methods
Animals

Myeloid cell-specific Hif1a null (HIF1α KO) (B6.129Hif1atm3Rsjo/J x B6.129P2-Lyz2tm1(cre)Ifo/J), iNOS
KO (B6.129P2-iNOStmLau/J), and normal C57Bl6/NJ
mice were purchased from Jackson labs. Male adult mice
(3–4 months-old) were housed individually (12 h:12 h
day:night cycle) in a temperature- and humidity-controlled environment (73.5 ± 5.5 °F and 50 ± 20%, respectively) and fed standard chow (LabDiet 5001, Purina
Mills, LLC, St. Louis, MO) and water ad libitum. Mice
were utilized for experimentation following a 7-day acclimation period and randomized into treatment groups
by body weight. All studies were conducted in accordance with the GSK Policy on the Care, Welfare and
Treatment of Laboratory Animals. All protocols were
reviewed and approved by the Institutional Animal Care
and Use Committee of GSK.

Mice were placed on a warming plate (30–32 °C) and
anesthetized using 2%/L O2 isoflurane. Right hind limbs
were first shaved and then pinned at the knee at 90° with
foot strapped into a mouse “shoe” which doubles as a
motor arm and force transducer (Aurora Scientific Instruments 305C, Aurora). Platinum sub-dermal electrodes (Grass Instruments; West Warwick, RI) were
inserted dorsally and ventrally to the femur for field
stimulation of the sciatic nerve. Because the mouse
gastrocnemius, plantaris, and soleus muscles are larger
and stronger as a complex than the ankle dorsiflexors
(TA and EDL), hind limbs produced a net plantarflexion
response to sciatic activation. Tetanic stimuli of 150 Hz
at 200 μs pulse width (with 2 mA current and 15 V) for
0.8 s were recorded as maximal isometric limb forces
while single 200 μs pulses were used to elicit maximal
twitch force values. Muscle contractility was evaluated
immediately prior to injury (baseline force day 0), day 1
post-injury, and then at varying longitudinal points
thereafter (as indicated).
Eccentric contraction-induced muscle injury

To induce muscle injury, mice were positioned as described above and initial baseline maximal twitch and
tetanic limb force measurement were performed. After a
2-min rest interval, mice underwent a unilateral eccentric muscle contraction protocol in which the hind limb
plantarflexor muscles were forcibly lengthened using the
automated footplate (30° angular rotation, 1800°/s) while
being concomitantly stimulated to contract (150 Hz;
200 μs pulse width; 2 mA and 15 V). A bout of eccentric
exercise consisted of 1 forced lengthening contraction
every 10 s for a total of 60 repetitions.

In vivo reagents

GSK1120360 (GSK360) was formulated in 0.5% hydroxypropylmethylcellulose (Acros Organics, Lot#A0320015,
Code 244020010, CAS 9004-65-3) and 0.1% Tween80
(Fisher, Lot#141362, Cat# T164-500) (HPMC:Tween) vehicle and administered (PO) daily at specified doses beginning on the day of eccentric damage (with the exception of
the experiment in Fig. 1b, with timings as indicated). The
iNOS-specific inhibitor 1400 W (20 mg/kg) and recombinant mouse erythropoietin (EPO) (20 μg/kg) were injected
subcutaneously in saline-based vehicles. 1400 W was administered 2-h prior to eccentric damage, while EPO was
dosed daily for 3 days leading up to the day of damage. For
EPO neutralization, 600 μg of a monoclonal antibody targeting EPO (R&D Systems, MAB959) was injected SC at

Histology

With the muscle still in situ, an ink mark was made on
the muscle belly to serve as a guide for reproducible collection of sections for analysis. Following excision, the
gastrocnemius muscles were oriented to provide cross
sectional fiber profiles when sectioned. A small drop of
OCT media (Sakura Finetek, USA) was placed on a cork
circle and the muscle was stabilized by placing the distal
end of the muscle into the media. The muscle was maintained in a vertical position while immersing it into liquid nitrogen cooled isopentane for 10 to 15 s until
frozen; samples were held at − 80 °C until sectioned.
Ten-micrometer frozen sections were prepared in a
cryostat and mounted on glass slides. Tissue sections
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were fixed with 4% paraformaldehyde diluted in PBS for
5 min at room temperature immediately prior to immunohistochemistry (IHC). Immunostaining was carried
out on an automated system (Ventana Medical, USA).
Briefly, the sections were blocked with 10% normal goat
serum for 32 min at 37 °C prior to application of a cocktail of anti-laminin and anti-albumin antibodies.
Anti-laminin (Ab44941, Abcam, USA) and anti-albumin
antibody (Ab19196, Abcam, USA) were applied at 5 μg/
ml and 1:10000 respectively for 1 h at 37 °C. Albumin
and laminin were detected using species-specific fluorophore conjugated secondary antibodies. Albumin immunoreactivity was demonstrated using an Alexa594
conjugate (A-11037, Invitrogen, USA) at 5 μg/ml and laminin expression using an Alexa488 conjugate (A-11006,
Invitrogen, USA) at 10 μg/ml; incubation in detection
antibodies was for 45 min at 37 °C. Following automated
wash steps the nuclei were stained using DAPI (D-3571,
Invitrogen, USA) then cover slipped using an aqueous
mounting media (P36961, Invitrogen, USA). Stained sections were imaged at × 20 magnification on the Zeiss
AxioScan.
Quantitative image analysis

A bespoke image analysis algorithim was developed (Definiens, Inc., USA) for use with Definiens Architect XD (Definiens AG, Germany) software. The entire cross-sectional area
of the scanned gastronemius muscle was included in the
analysis using the above software. Laminin expression was
used to isolate individual cross-sectional myofibers. These individual fibers were assessed for their expression of albumin
(Optical Density) as well as additional morphometric parameters (e.g., perimeter, area, roundness, myonuclei count and
intracellular distribution). Individual fiber data were exported
to CSV files for statistical analysis.
Gene expression analyses

Mouse gastrocnemius samples were collected and flash
frozen in liquid nitrogen then stored at − 80 °C. For
RNA isolation, ~ 100 mg samples were used in 1 ml Trizol and isolation was done according to the manufacturers protocol (Ambion Cat #15596-068). Purified RNA
went through Qiagen RNA clean up kit (Cat #74204)
and eluted in 50 μl elution buffer. For each sample 2 μg
total RNA was submitted to Q2 Solutions for Affymetrix
analysis, using Affymetrix Gene Chip Mouse Genome
430A 2.0 Array. Raw data files (CEL files) were then
pre-processed using the RMA (Robust Multi-chip Average) pipeline [41] in combination with the most current
re-annotated probeset definitions [42]. To determine differential mRNA expression, a linear model was fit [43,
44]. The false discovery rate (FDR) was computed as an
adjusted P value [45] to account for multiple testing and
a cut-off of 10% FDR was used to define differential
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expression. For BMDM work, RNA was isolated from
BMDM using a Turbo Capture plate and kit (Qiagen)
per manufacturer’s protocol. iNOS expression was quantitated by Taqman qRT-PCR using. Housekeeping genes,
Ppia (PRIMERS) and Rpl-p0 (PRIMERS), were used to
normalize expression. Data are presented as ΔCt.
Plasma assessment of mouse erythropoietin

Plasma EPO and VEGF concentrations were measured
using mouse/rat EPO/VEGF serum/plasma multiplexed
immunoassay (Meso Scale Discovery, Gaithersburg,
MD) according to manufacturers’ protocols.
Bone marrow-derived macrophage generation

Tibia and femurs from wild type mice were stripped of
muscle tissue and the marrow flushed using a 24-G needle and syringe filled with basal culture media (RPMI
1640 + Glutamax (Gibco), 10% fetal bovine serum
(Gibco), 5% horse serum (Gibco), and 1% antibiotic/antimycotic (Gibco)). Isolated marrow cells were gently triturated to a uniform suspension and then filtered
through a 40-μm cell strainer. The cell suspension was
then centrifuged (500g for 5 min) and the resultant pellet resuspended in 1× Red Blood Cell Lysis Buffer (Miltenyi Biotec) and gently agitated for 3 min to lyse red
blood cells. The cell suspension was centrifuged, and the
resultant pellet resuspended in basal culture media to a
final cell concentration of 107 cells/ml. Cells were cultured at an initial density of 1.5 × 106 in 10 cm bacteriological dishes in basal culture media supplemented with
10 ng/ml macrophage colony stimulating factor (MCSF;
R&D Systems). At day 4 post-plating, cells were supplemented with basal culture media + 10 ng/ml MCSF.
BMDMs were polarized and treated with GSK360 on
day 7. To generate M1 macrophages, basal culture
media was supplemented with 20 ng/ml recombinant
mouse IFNγ (Millipore, cat #407320) + 100 ng/ml of
lipopolysaccahride (LPS; SigmaAldrich, cat# L5293). For
M2 activation, basal culture media was supplemented
with 20 ng/ml recombinant mouse IL-4 (R&D Systems,
cat# 404-ML). For naïve, M0 macrophages, only basal
culture media was used. GSK360 was then added to designated cultures at a final concentration of 10 μM, with
DMSO added as a vehicle control. BMDM were cultured
for a final 24 h at 37 °C then isolated by gently pipetting
using ice cold PBS (Gibco, pH 7.4) following incubation
on ice for 10 min. The suspension was then centrifuged,
and the resultant cell pellets processed for either
RT-PCR or Western blotting.
Adoptive transfer of BMDM

Bone marrow from the tibia and femurs of myeloid
HIF1α KO and HIF1α WT littermates were used to culture bone marrow-derived macrophages (BMDMs) as
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described above. Seven days following initial culture,
BMDMs were lifted from culture dishes with Accutase
(Gibco). Cell suspensions were pooled in 50-ml conical
tubes, centrifuged (500g for 5 min), resuspended in
serum-free RPMI 1640, counted for cell density numbers, and centrifuged again to pellet. BMDMs were then
labeled with PKH67 Green according to manufacturer’s
protocol (Sigma-Aldrich). Once labeled, BMDMs were
rinsed three times with sterile saline and resuspended at
two million cells per 100 μl.
Myeloid HIF1α KO recipient animals were randomized by body weight and initial tetanic force production.
Animals were anesthetized, and the eccentric exercise
protocol was performed as described above. Immediately
following the exercise protocol, 100 μl of BMDM suspension (either HIF1α KO or HIF1α WT) were introduced directly to the injured gastrocnemius via
intramuscular injection. Animals were then treated with
either vehicle or GSK360 (N = 8 for each group). At 24 h
post-eccentric damage, force production was assessed as
described above.
FACS analysis

Muscle tissues were minced and treated with LiberaseTM (Roche) and Dnase I for 2 h at 37 °C. After digestion, tissue homogenates were filtered through 70 μm
strainers for cell suspension. For flow cytometry assay,
cells were first treated with Fc Block (1:1000; BioLegend), followed by staining surface antigens with UV viability dye (Zombie 1:400; BioLegend), CD11b-PE (M1/
70, 1:400), Ly6C-PerCP/Cy5.5 (HK1.4, 1:400), CD45-PE/
Cy7 (30-F11, 1:1000) and I-A/I-E (M5/114.15.2, 1:400).
Macrophages were labeled with F4/80 mAb (45-4801-80,
ThermoFisher). Data were acquired on FACS Aria II and
analyzed by FlowJo V10.2.
Western blotting

BMDM cell pellets were resuspended in T-PER lysis buffer (Life Technologies) supplemented with Halt™ protease inhibitor cocktail and EDTA (Life Technologies).
Suspensions were incubated on ice for 20 min with periodic vortexing, then centrifuged to clarify. Supernatants
were assayed for protein content using a microplate
BCA assay (ThermoFisher) per manufacturer’s protocol.
For each sample, a total of 10 μg of protein were separated on a 4–12% Bis-Tris Bolt™ SDS-PAGE gels (Life
Technologies) and transferred to nitrocellulose membranes using an iBlot2 (Life Technologies).
Gastrocnemius muscles were dissected and snap frozen. Approximately 50 mg of frozen tissue was lysed in
T-PER lysis buffer (Life Technologies) supplemented
with Halt™ protease inhibitor cocktail and EDTA (Life
Technologies) using an MPBio Bead Blender. Lysates
were incubated on ice for 20 min and then centrifuged
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to clarify. Supernatants were assayed for protein content
using a microplate BCA assay (ThermoFisher) per manufacturer’s protocol. For each sample, 50 μg of protein
was separated on 4–12% Bis-Tris Bolt™ SDS-PAGE gels
(Life Technologies) and transferred to nitrocellulose
membranes using an iBlot2 (Life Technologies). The
same sham samples were run on each blot for both 1 h
and 24 h time points for comparison to baseline.
Membranes were blocked using Superblock TBS +
Tween-20 (ThermoFisher) for 1 h at room temperature.
Primary antibodies, diluted in Superblock TBS +
Tween-20, were added to the membranes and incubated
overnight at 4 °C on a platform rocker. Membranes were
washed three times for 15 min at room temperature
with TBS + 0.5% Tween-20 (ThermoFisher). Secondary
antibodies, diluted in Superblock TBS + Tween-20, were
then added to the membranes and incubated for 4 h at
room temperature, protected from light. Membranes
were then washed as before and imaged on an Odyssey
CLx (Li-Cor Systems). Mouse anti-iNOS (BD Transduction Labs, clone 6/iNOS) used at a dilution of 1:1000;
rabbit anti-Rab5 (Cell Signaling Technologies) used at a
dilution of 1:1000; goat anti-HIF1a (R&D Systems) used
at a dilution of 1:1000; donkey anti-mouse 680RD secondary antibody (Li-Cor Biosystems) used at a dilution
of 1:10,000; donkey anti-rabbit 800CW (Li-Cor Biosystems) used at a dilution of 1:10,000; donkey anti-goat
800CW (Li-Cor Biosystems) used at a dilution of
1:10,000.
HIF1α ELISA

BMDMs polarized to M0, M1, or M2 (as described
above) were treated with GSK360 for 24 h (n = 2 per
dose point). Cells were then lysed using T-PER lysis buffer (Life Technologies) supplemented with Halt™ protease inhibitor cocktail and EDTA (Life Technologies).
Resultant suspensions were incubated on ice for 20 min
with periodic vortexing then centrifuged to clarify. Supernatants were assayed for protein content using a microplate BCA assay (ThermoFisher) per manufacturer’s
protocol. Samples were run in triplicate in a DuoSet
HIF1α ELISA (R&D Systems), following the standard
protocol. Data was captured with a SpectraMax spectrophotometer and analyzed using GraphPad Prism 7.0.
Preclinical statistical analysis

For each experiment, the means and SEM of the parameters measured were determined. Statistical analyses
were performed using Student’s t test in single-factorial
designs. For multifactorial study designs, one- or
two-way ANOVA was used as appropriate. Tukey’s (for
one-way ANOVA) or Bonferroni (for two-way ANOVA)
post hoc test was applied when significant differences
were found. Testing for normal variance was performed
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and confirmed. For mouse experiments, the number
of mice per group required to detect biologically significant effect sizes was calculated using an appropriate statistical sample-size formula and indicated in
the biometrical planning section of the animal license
submitted to the governing authority. Blinding was
not done during animal group allocation but was
done for some measurements made in the study (i.e.,
histology). No specific exclusion criteria were applied,
as inbred strains, which display uniform phenotypic
characteristics, were used exclusively. Analyses were
carried out with SigmaPlot v.12 software (Systat Software GmbH, Erkrath) or GraphPad Prism software
(GraphPad Software, San Diego). P < 0.05 was considered statistically significant.
Clinical methods
Eccentric exercise-induced muscle damage in healthy
volunteers

This was a repeat dose, two-cohort, randomized,
placebo-controlled, parallel group study in healthy volunteers (Clinicaltrials.gov reference NCT02231190). In
each cohort, approximately 30 subjects were enrolled
and randomized into a 1:1 ratio between daprodustat
and placebo groups (study CONSORT diagram, Additional file 4: Figure S3). The study protocol, any amendments, the informed consent, and other information that
required pre-approval were reviewed and approved by
an investigational center institutional review board, in
accordance with the International Conference on
Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Good
Clinical Practice (GCP) and applicable country-specific
requirements, including United States (US) 21 Code of
Federal Regulations (CFR) 312.3(b) for constitution of
independent ethics committees.
This study was conducted in accordance with ICH
GCP and all applicable subject privacy requirements and
the ethical principles that are outlined in the Declaration
of Helsinki 2008. The study was monitored in accordance with ICH E6, Section 5.18. Investigators were
trained to conduct the study in accordance with GCPs
and the study protocol as defined in ICH E3, Section
9.6. Written commitments were obtained from investigators to comply with GCP and to conduct the study in
accordance with the protocol.
Written informed consent was obtained from each
subject prior to the performance of any study-specific
procedures. The investigator agreed to provide the subjects as much time as necessary to review the document,
to inquire about details of the trial, and to decide
whether or not to participate in the study. The informed
consent was signed and dated by the study subjects and
by the person who conducted the informed consent

Page 10 of 14

discussion. Electronic case report forms were provided
for each subject’s data to be recorded.
Study methods

Subjects who met all screening criteria were enrolled
and admitted to the clinical test center 1 day before the
exercise protocol. Subjects who had a creatine kinase
(CK) within the normal range at baseline participated in
the study. Ten minutes before the exercise protocol,
range of motion, muscle pain/soreness, and MVC were
measured. The exercise protocol was then conducted on
the same arm (details below). Subjects who achieved a
deficit from baseline of at least 40% in their MVC were
randomized to either daprodustat or placebo and entered the post-exercise phase. Fifteen minutes after completion of eccentric exercise, each subject started to
receive a total of five oral doses of daprodustat or placebo on day 1 (0 h, 4 h, 8 h), day 2 (24 h), and day 3
(48 h). Functional assessments performed pre-exercise
were repeated at 5 min, 30 min, 24 h, 48 h, and 72 h
post-exercise. Subjects were discharged from the unit on
day 4 and returned for a follow-up visit 7–10 days later.
The study was performed in two separate cohorts. In
cohort 1, subjects were randomized to either placebo or
5 mg daprodustat. In cohort 2, subjects were randomized to either placebo or 50 mg daprodustat. The progression to the second cohort, termination of study, or a
repeat of the same dose level was based on the feasibility
of the eccentric exercise protocol and the totality of the
data. The data sets reviewed, at minimum, consisted of
safety data and observed MVC at 90° of flexion. This
study was double-blinded with respect to the subjects,
the investigator and site staff (with the exception of the
site pharmacist). GlaxoSmithKline (GSK) was un-blinded
throughout the study. This study was performed in compliance with Good Clinical Practices and GlaxoSmithKline Standard Operating Procedures for all processes
involved, including the archiving of essential documents.
Anonymized individual participant data and study documents can be requested for further research from
www.clinicalstudydatarequest.com.
Inclusion criteria

Subjects were eligible for inclusion in this study only if
all of the following criteria were met:
1. Males between 18 and 35 years of age inclusive, at
the time of signing the informed consent.
2. Healthy as determined by a responsible and
experienced physician, based on a medical
evaluation including medical history, physical
examination, laboratory tests, and cardiac
monitoring.
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3. Body weight ≥ 70 kg and BMI within the range 22.0
to 34.0 (inclusive).
4. Capable of giving written informed consent, which
included compliance with the requirements and
restrictions listed in the consent form.
5. ALT, alkaline phosphatase, and bilirubin ≤ 1.5 × ULN.
6. QTc < 450 ms based on single or average QTc
value of triplicate values obtained over a brief
recording period.
7. At least a 1 year history of no regular (2–3 times
per week) exercise and no heavy exertion within
past week.
8. No strenuous exercise involving the arms during
the last 10 weeks.
Eccentric exercise protocol

Each subject performed maximal eccentric contractions
of the elbow flexors of one arm against a lever arm moving at a constant (isokinetic) angular velocity over a limited range of motion. The aim of this procedure was to
elicit at least a 40% decline in isometric strength from
the start to the end of the exercise. To take account of
variability in performance between individuals, the exercise procedure was repeated up to three times in total to
elicit this deficit. Subjects not manifesting at least a 40%
decline in isometric strength were excluded from the
study. Each subject will be placed on a Cybex with the
lever arm fixed so that the elbow was at 90° flexion. The
subject was then asked to provide an MVC of the elbow
flexors by pulling against the lever arm while force production is measured. The MVC was measured three
times in succession and the highest value recorded. This
value was used as a reference assessment of volunteer
performance in the subsequent exercise protocol. After a
2-min rest, subjects were asked to perform five sets of
six maximal eccentric contractions of the elbow flexors
of the non-dominant arm to induce local muscle inflammation, pain and transient functional deficits. Each eccentric contraction started at an elbow angle of 90o
flexion and volunteers were asked to pull against the
lever arm before the lever arm extended to 180o at a
constant angular velocity of 60o/s. Subjects were verbally
encouraged to maximally resist the lowering lever arm
of the ergometer during the eccentric movement flexion.
At the end of each eccentric contraction, each subject
was instructed to relax and the lever arm returns to the
90o flexion position at an angular velocity of 10o/s before
the next eccentric contraction. Each bout of 6 contractions was separated by 2 min of resting recovery. At the
end of the five sets, after a 2-min rest period, the subject
was asked to provide another MVC. At this point, the instructor calculated the acute post-exercise MVC deficit. If
post-exercise MVC was < 40% lower than pre-exercise,
this triggered a second round of 30 eccentric contractions.
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If post-exercise MVC was > 40% lower than pre-exercise,
the exercise was considered complete. For the subjects entering a second round of eccentric exercise, they repeated
five sets of six maximal eccentric contractions with a
2-min rest period between sets as above. At the end of the
five sets, after a 2-min rest period, the subjects were asked
to provide an MVC. If post-exercise MVC was > 40%
lower than pre-exercise, the exercise was considered
complete. There was provision to go to a third round of
exercise if post-exercise was < 40% of pre-exercise MVC
but every subject in the study achieved a > 40% deficit
within two exercise rounds.
Study objectives and endpoints

The primary objective of the study was to evaluate the protective effects of daprodustat on eccentric exercise-induced
muscle injury by measuring MVC of the exercised arm up to
72 h after completion of eccentric exercise in subjects treated
with daprodustat in comparison to subjects treated with placebo. Secondary objectives included assessment of the safety
and tolerability of daprodustat by measuring adverse events,
vital signs (systolic and diastolic blood pressure, pulse rate,
and respiratory rate), 12-lead electrocardiogram (ECGs)
(heart rate, PR, QRS, QT, and QTcF), and laboratory parameters (Additional file 6: Table S3). Another secondary objective was to evaluate the protective effects of daprodustat on
deficits in arm range of motion after eccentric exercise by
measuring change in degree of motion and resting arm angle
from post-exercise up to 72 h after completion of eccentric
exercise in subjects treated with daprodustat in comparison
to subjects treated with placebo.
Measurement of MVC isometric strength

Strength was assessed in the non-dominant arm by a maximal isometric (fixed length) contraction. The subject was
placed on a Cybex ergometer (Medway, MA) in a
semi-supine position grasped the dynamometer handle with
the wrist in a supinated position. MVC was measured at
both 90° and 150° of extension at the elbow (90° and 30° of
flexion respectively). While the subject was seated, the lever
arm was fixed so that the elbow was at the appropriate angle
(90° and 150° of extension/90° and 30° of flexion respectively). The subject was then asked to provide a maximal voluntary contraction of the elbow flexors by pulling against the
lever arm while force-production was measured. The MVC
was measured three times in succession at each angle, with a
30 s rest between attempts. The highest value at each angle
was recorded.
Measurement of elbow range of motion (ROM)

A manual goniometer was used to measure the range of
motion at the elbow. Joint angles were measured at rest,
at maximum extension and at maximum flexion. Measurements were taken twice for each joint angle and the
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mean value of the two measurements was used to calculate the ROM by subtracting the flexion angle from the
extension angle.
Somascan serum analysis

Baseline and 72 h serum samples from Cohort 2 were
examined with an aptamer-based proteome analysis
screen (SOMAlogic Inc., SOMAscan® Boulder, CO,
Fig. 3d and Additional file 7: Table S4). Protein concentration data was log2 transformed and normalized using
quantile normalization [44]. To determine differential
expression, a linear model was fit [43] taking into account the treatment effect as well as the pair wise design
(i.e., samples from the same individual before and after
treatment). The false discovery rate (FDR) was computed
as an adjusted P value to account for multiple testing
and a cutoff of 10% FDR as well as an absolute fold
change cutoff of 1.5 or greater was used to define differential expression. All analyses were done using the R/
Bioconductor and ggplot2 software packages [46].
Clinical statistical analysis

Clinical primary endpoints were analyzed using a
ANCOVA model with a fixed term of treatment regimen,
visit, interaction of regimen and visit, baseline endpoint as
a covariate and subject as a random effect. Point estimate
and its 95% confidence interval were obtained from the
model for comparisons of interests (e.g., active doses versus placebo at each visiting time point). Biomarkers, including serum CK activity, after logarithm transformation,
were analyzed with a repeat measure ANOVA with fixed
terms of regimen, visit and interaction of regimen and
visit, subject as random effects.

Additional files
Additional file 1: Figure S1. Prolyl hydroxylase inhibitors protect
muscle at doses that raise EPO but not VEGF. (a) Effect of different daily
doses of GSK360 on contraction induced injury in mice. Mice were
treated with vehicle or the indicated dose of GSK360 daily. Data are
normalized to pre-damage force (n = 8). (b) Effect of co-treatment with
EPO neutralizing antibody and GSK360 for 3 days on circulating red
blood cells and hematocrit (n = 8). All data in the figure are shown as the
mean ± SEM. Two-way ANOVA followed by Holm-Sidak’s test corrected
for multiple comparisons; **P < 0.01 as compared to vehicle dosed
cohort. (PDF 224 kb)
Additional file 2: Figure S2. Prolyl hydroxylase inhibitors do not alter
transcriptional profiles in skeletal muscle. (a) Transcriptional profile in
mouse gastrocnemius muscle 9 h after injury with 10 mg/kg GSK360 or
vehicle. After correcting for multiple testing, no statistically significant
changes were detected. (b) Relative tissue concentration of GSK360 after
4 h of IV infusion (n = 3). (c) Flow cytometry quantification of F4/80
positive macrophages in muscle 0–14 days after muscle injury with
10 mg/kg GSK360 or vehicle (n = 4). (d) Quantification of HIF1α in
polarized murine bone marrow-derived macrophages (BMDM) following
24 h of GSK360 treatment. Protein extracts from BMDMs were generated
(n = 2). HIF1α was quantified via DuoSet ELISA (R&D Systems) with protein
extracts. All data in the figure are shown as the mean ± SEM. Two-way
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ANOVA followed by Holm-Sidak’s test corrected for multiple comparisons;
**P < 0.01 as compared to vehicle dosed cohort. (PDF 257 kb)
Additional file 3: Table S1. Excel file of Affymetrix Gene Chip mRNA
levels from mouse gastrocnemius muscle 3, 6 and 9 hrs after injury with
10 mg/kg GSK360 vehicle. Table shows comparison of expression levels
between vehicle and GSK360 treated muscle. (XLSX 1910 kb)
Additional file 4: Figure S3. Daprodustat does not alter arm range of
motion after eccentric exercise. (a) Effect of different daily doses of
daprodustat on contraction induced injury in mice. Mice were treated
with vehicle or the indicated dose of daprodustat daily. Data are
normalized to pre-damage force (n = 9). (b) Arm range of motion,
measured with a manual goniometer was recorded 10 min pre-exercise
and 5 min, 30 min, 24 h, 48 h, and 72 h post exercise. The boxed area
represents a 75% range of values with the central line indicating the
median and the cross the mean value. Individual values are displayed to
the left (top panel placebo vs GSK863 5 mg (n = 14, n = 12), bottom panel
placebo vs GSK863 50 mg (both n = 15)). (PDF 270 kb)
Additional file 5: Table S2. Demographic data for the two healthy
volunteer studies. Twenty-six healthy volunteers were randomized in
Cohort 1, 30 were randomized in cohort 2, with approximately 1:1 ratio
of daprodustat vs. placebo. All randomized subjects completed the study,
and the data from all randomized subjects were included in the study
analyses. Overall, demographic characteristics were similar among the
placebo and GSK127863 groups. No violation of the treatment assignment
or broken blinding occurred in this study. No significant protocol deviations
were found during the study. (PDF 200 kb)
Additional file 6: Table S3. Summary of adverse events. No serious
adverse events (SAEs) were reported in this study. Fifteen subjects (26.8%)
reported adverse events (AEs). The most commonly reported AEs
(> 1 subject) were myalgia in nine subjects (16.1%), headache in two
subjects (3.6%), and peripheral swelling in two subjects (3.6%). Myalgia
was largely limited to arm pain during and after the exercise. Single
events of vomiting and pollakiuria, both in the placebo group, were not
considered by the investigator as related to study drug. No AEs led to
withdrawal of subjects from this study. There were no clinically significant
findings of vital signs, ECG or clinical laboratory parameters. (PDF 196 kb)
Additional file 7: Table S4. Effect of daprodustat on serum protein
changes pre- and 3 days post exercise. Excel file for SOMAscan®
(SOMAlogic Inc.) aptamer-based proteome analysis of serum comparing
baseline (pre-injury) and 72 h post-injury serum samples from Cohort 2 of
the healthy volunteer study. Protein concentration data was log2
transformed and normalized using quantile normalization [44]. To
determine differential expression, a linear model was fit [43] taking into
account the treatment effect as well as the pair wise design (i.e., samples
from the same individual before and after treatment). (PDF 1428 kb)
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